

RESEARCH ARTICLE


# Variation in lung function and alterations in cardiac structure and function—Analysis of the UK Biobank cardiovascular magnetic resonance imaging substudy

Ross J. Thomson<sup>1</sup>, Nay Aung<sup>1</sup>, Mihir M. Sanghvi<sup>1</sup>, Jose Miguel Paiva<sup>1</sup>, Aaron M. Lee<sup>1</sup>, Filip Zemrak<sup>1</sup>, Kenneth Fung<sup>1</sup>, Paul E. Pfeffer<sup>1,2</sup>, Alexander J. Mackay<sup>2a</sup>, Tricia M. McKeever<sup>3</sup>, Elena Lukaschuk<sup>4</sup>, Valentina Carapella<sup>4</sup>, Young Jin Kim<sup>4</sup>, Charlotte E. Bolton<sup>3</sup>, Stefan K. Piechnik<sup>4</sup>, Stefan Neubauer<sup>4</sup>, Steffen E. Petersen<sup>1\*</sup>

**1** William Harvey Research Institute, NIHR Biomedical Research Centre at Barts, Queen Mary University of London, London, United Kingdom, **2** Barts Health NHS Trust, London, United Kingdom, **3** Nottingham Respiratory Research Unit, NIHR Nottingham Biomedical Research Centre, School of Medicine, City Hospital NUH Trust Campus, University of Nottingham, Nottingham, United Kingdom, **4** Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

<sup>a</sup> Current address: National Heart and Lung Institute, Imperial College, London, United Kingdom

\* [s.e.petersen@qmul.ac.uk](mailto:s.e.petersen@qmul.ac.uk)



**OPEN ACCESS**

**Citation:** Thomson RJ, Aung N, Sanghvi MM, Paiva JM, Lee AM, Zemrak F, et al. (2018) Variation in lung function and alterations in cardiac structure and function—Analysis of the UK Biobank cardiovascular magnetic resonance imaging substudy. *PLoS ONE* 13(3): e0194434. <https://doi.org/10.1371/journal.pone.0194434>

**Editor:** Yoshihiro Fukumoto, Kurume University School of Medicine, JAPAN

**Received:** December 10, 2017

**Accepted:** March 3, 2018

**Published:** March 20, 2018

**Copyright:** © 2018 Thomson et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** UK Biobank encourages and provides as wide access as possible to its data and samples for health-related research in the public interest by all bona fide researchers from the academic, charity, public, and commercial sectors, both in the UK and internationally, without preferential or exclusive access for any user. Data can be sought directly from UK Biobank via online application at <http://www.ukbiobank.ac.uk/register-apply/>.

## Abstract

### Background

Reduced lung function is common and associated with increased cardiovascular morbidity and mortality, even in asymptomatic individuals without diagnosed respiratory disease. Previous studies have identified relationships between lung function and cardiovascular structure in individuals with pulmonary disease, but the relationships in those free from diagnosed cardiorespiratory disease have not been fully explored.

### Methods

UK Biobank is a prospective cohort study of community participants in the United Kingdom. Individuals self-reported demographics and co-morbidities, and a subset underwent cardiovascular magnetic resonance (CMR) imaging and spirometry. CMR images were analysed to derive ventricular volumes and mass. The relationships between CMR-derived measures and spirometry and age were modelled with multivariable linear regression, taking account of the effects of possible confounders.

### Results

Data were available for 4,975 individuals, and after exclusion of those with pre-existing cardiorespiratory disease and unacceptable spirometry, 1,406 were included in the analyses. In fully-adjusted multivariable linear models lower FEV<sub>1</sub> and FVC were associated with smaller left ventricular end-diastolic (−5.21 ml per standard deviation (SD) change in FEV<sub>1</sub>, −5.69 ml per SD change in FVC), end-systolic (−2.34 ml, −2.56 ml) and stroke volumes

**Funding:** SEP, SN and SKP acknowledge the British Heart Foundation for funding the manual analysis to create a cardiovascular magnetic resonance imaging reference standard for the UK Biobank imaging resource in 5000 CMR scans ([www.bhf.org.uk](http://www.bhf.org.uk); PG/14/89/31194). SEP acts as a paid consultant to Circle Cardiovascular Imaging Inc., Calgary, Canada. NA is supported by a Wellcome Trust Research Training Fellowship ([wellcome.ac.uk](http://wellcome.ac.uk); 203553/Z/Z). KF is supported by the Medical College of Saint Bartholomew's Hospital Trust ([www.bartscharity.org.uk](http://www.bartscharity.org.uk)). AL and SEP acknowledge support from the National Institute for Health Research (NIHR) Cardiovascular Biomedical Research Centre at Barts and from the "SmartHeart" EPSRC programme grant ([www.nihr.ac.uk](http://www.nihr.ac.uk); EP/P001009/1). SN and SKP are supported by the Oxford NIHR Biomedical Research Centre and the Oxford British Heart Foundation Centre of Research Excellence. TMM and CEB are supported by the NIHR Nottingham Biomedical Research Centre. This project was enabled through access to the MRC eMedLab Medical Bioinformatics infrastructure, supported by the Medical Research Council ([www.mrc.ac.uk](http://www.mrc.ac.uk); MR/L016311/1). The funders provided support in the form of salaries for authors as detailed above, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the 'author contributions' section.

**Competing interests:** Professor Steffen Petersen provides consultancy to Circle Cardiovascular Imaging Inc., Calgary, Canada. The other authors declare that they have no competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

(−2.85ml, −3.11ml); right ventricular end-diastolic (−5.62ml, −5.84ml), end-systolic (−2.47ml, −2.46ml) and stroke volumes (−3.13ml, −3.36ml); and with lower left ventricular mass (−2.29g, −2.46g). Changes of comparable magnitude and direction were observed per decade increase in age.

## Conclusions

This study shows that reduced FEV<sub>1</sub> and FVC are associated with smaller ventricular volumes and reduced ventricular mass. The changes seen per standard deviation change in FEV<sub>1</sub> and FVC are comparable to one decade of ageing.

## Introduction

Respiratory disease is common and under-diagnosed, and a significant and growing cause of death and disability[1]. Much of the excess morbidity and mortality is secondary to cardiovascular disease[2]. In a prospective cohort study of 7,575 patients with chronic obstructive pulmonary disease (COPD) from Saskatchewan, Canada[3], the quintile of patients with the most severe COPD had relative risks between 1.4 and 3.1 for all-cause mortality, cardiovascular mortality, congestive heart failure, and angina.

Lung function is independently associated with cardiovascular morbidity and mortality [4,5], both in individuals with established respiratory disease and in those without any diagnosis or symptoms. In a prospective study of 15,000 individuals in the west of Scotland[6], those in the lowest quintile for forced expiratory volume in first second (FEV<sub>1</sub>) had an all-cause mortality almost twice that of the highest quintile. The risks were similar in asymptomatic (subclinical) individuals.

The prevalence of subclinical impaired lung function is great: in the National Health and Nutrition Examination Survey (NHANES) and NHANES III cohort studies of community volunteers in the United States[7] around 12–13% of individuals had an FEV<sub>1</sub> to forced vital capacity (FVC) ratio less than 0.7, the generally accepted cut-off for obstructive lung disease [8]. Almost three quarters of these individuals did not have a diagnosis of lung disease, and most of the undiagnosed individuals reported good or excellent health. Mortality was higher in those with abnormal spirometry, irrespective of the presence of diagnosed lung disease.

Previous work has explored some of the relationships between lung disease and cardiovascular structure. Using data from the MESA cohort, Grau and colleagues[9] demonstrated that increasing emphysema severity, quantified with thoracic computed tomography, is associated with lower right ventricular volumes and mass. They also found that right ventricular mass is associated with the FEV<sub>1</sub> to FVC ratio. Barr *et al.*[10] continued this analysis to identify similar relationships between emphysema severity and left ventricular volumes and mass, and between the FEV<sub>1</sub> to FVC ratio and left ventricular end-diastolic and stroke volumes. These analyses were conducted in an all-comers population, many of whom had existing cardiovascular and respiratory disease. Furthermore, the effects of FEV<sub>1</sub> and FVC *per se* were not studied. Given the prevalence of subclinical changes in lung function, together with the associations with adverse outcomes, we set out to explore the relationships between lung function and cardiovascular structure and function in a population free from diagnosed cardiovascular and respiratory disease.

## Methods

UK Biobank is a large prospective cohort study of approximately 500,000 unselected community volunteers aged 40 to 69 at the time of enrolment, living in the United Kingdom. The design and conduct of the study have been described in detail previously[11]. This study was covered by the general ethical approval for UK Biobank studies from the NHS National Research Ethics Service on 17<sup>th</sup> June 2011 (Ref 11/NW/0382). None of the authors had direct contact with the study participants. This report is a cross-sectional analysis of the subset of participants who took part in the imaging pilot programme.

Demographics and doctor-diagnosed co-morbidities were self-reported by electronic questionnaire and interview with a healthcare professional. Data collected during the imaging visit were used in the analyses, except where unavailable, in which case data from the enrolment visit were used. If a participant did not answer a question regarding a comorbid diagnosis, or did not know, it was assumed they did not have the condition. Physical measurements (height, weight, blood pressure, heart rate) and smoking status were captured exclusively at the time of imaging.

Smokers were defined as individuals who smoke, or used to smoke, on all or most days. Those who smoked occasionally were deemed to be never smokers. For current or previous smokers, pack year history was calculated as the product of the number of packs of cigarettes smoked per day and the difference between age started smoking and age stopped smoking (or age at imaging for current smokers).

## Cardiovascular magnetic resonance

A subgroup of participants is undergoing cardiovascular magnetic resonance imaging (CMR). The CMR acquisition protocol and post-processing have been described previously[12]. In brief, participants underwent imaging using a 1.5 Tesla Siemens MAGNETOM Aera scanner (Siemens Healthcare GmbH, Erlangen, Germany) at a central imaging centre. Short and long axis cine images were acquired using a balanced steady state free precession sequence. Manual image analysis was performed across two core imaging centres using cvi42 version 5.1.1 (Circle Cardiovascular Imaging, Calgary, Canada) by observers blinded to all clinical information. The software used these contours to calculate right and left ventricular end-diastolic, end-systolic, and stroke volumes; right and left ventricular ejection fraction; and left ventricular mass. The manual image analysis and quality control, including assessment of intra- and inter-observer variability, have been described in detail previously[13].

## Spirometry

Spirometry without bronchodilator administration was performed at the time of imaging according to a standard protocol using a Vitalograph Pneumotrac 6800 spirometer [14]. Each participant produced two blows, and a third if there was unacceptable variance in the first two (as calculated by the spirometer). The forced expiratory volume in one second (FEV<sub>1</sub>), forced vital capacity (FVC), and an automated assessment of measurement quality were recorded.

Spirometry blows were excluded from the analysis if the automated quality assessment was anything other than 'acceptable'. Participants were excluded if they had fewer than two acceptable blows, if the coefficient of variation for the two or three acceptable blows exceeded 5%, or if the difference between the best and second best acceptable blow exceeded 150ml, in accordance with established guidelines[8]. To investigate the potential impact of these exclusion criteria on the results we performed a sensitivity analysis in which all participants with at least two 'acceptable' spirometry blows were included, without any limit on the permissible range

or coefficient of variation between blows. The results of this sensitivity analysis are presented in [S2 File](#). Obstructive spirometry was defined as an FEV<sub>1</sub> to FVC ratio less than 0.7.

## Statistical analysis

The CMR-derived parameters and FEV<sub>1</sub> and FVC were approximately normally distributed and the assumptions for linear regression were satisfied. FEV<sub>1</sub> and FVC were standardised to the mean (FEV<sub>1</sub> mean 2.87 litres, SD 0.70 litres; FVC mean 3.73 litres, SD 0.89 litres).

The relationships between nine CMR-derived parameters and both FVC and FEV<sub>1</sub> were modelled with multivariable linear regression, using age, sex, ethnicity, height, weight, systolic blood pressure, resting heart rate, Townsend deprivation index (a commonly used measure of material deprivation where positive values represent above-average deprivation and negative values below-average deprivation), education level (categorised as the presence or absence of a degree or professional qualification), regular alcohol consumption (defined as three or more occasions per week), smoking history (pack years) and any diagnosis of hypertension or diabetes as co-variables. Height and weight were included as covariates in the regression models, rather than indexing the dependent variables to body surface area, since the use of ratios in regression analysis is liable to spurious results and misinterpretation[15,16]. The approach adopted ensures all variables in the model are appropriately adjusted for body composition.

To place the effects of spirometry on CMR-derived parameters in context, the relationships between the CMR-derived parameters and age were modelled in a similar fashion, except that both FEV<sub>1</sub> and FVC were used as co-variables. Interaction terms were used to explore any stratification by sex in the relationships between the CMR-derived parameters and the primary exposure variable (FEV<sub>1</sub>, FVC, or age) in each regression model.

Each regression analysis was performed on a complete-case basis without imputation of missing data. Nine of thirteen covariates had no missing data, and the covariate with most missing data (alcohol consumption) lacked fewer than one percent of observations. The outcome variables (CMR-derived parameters) had fewer than two percent missing observations, which were clustered in 22 participants who were missing all the outcome variables and another one who was missing right ventricular parameters.


Regression coefficients are presented as the change in the CMR-derived parameter per standard deviation change in FEV<sub>1</sub> or FVC, or per decade change in age. P values were calculated using Student's t test or ANOVA for continuous variables and Chi-squared test for categorical variables. Statistical analyses were performed using R version 3.3.2[17].

## Results

1,221 individuals were excluded on account of pre-existing cardiorespiratory disease, the definition of which is provided in [S1 File](#). Of the remaining 3,754 individuals, a further 2,348 were excluded in the primary analysis because they did not meet the criteria for reproducible and acceptable spirometry. The case selection process for the primary analysis is shown in [Fig 1](#).

1,406 participants were included in the primary analysis. On account of missing data, the number of observations in the regression models was 1,366 or 1,367 depending on the CMR-derived parameter being studied. Baseline characteristics, stratified by tertile of FEV<sub>1</sub>, are described in [Table 1](#). Compared to those in the highest tertile, those in the lowest tertile of FEV<sub>1</sub> were older, more likely to be female, shorter, lighter, had lower diastolic blood pressure and higher resting heart rates, and were more likely to have obstructive spirometry.

Following adjustment for potential confounders in a multivariable linear model, lower FEV<sub>1</sub> and FVC were associated with smaller left ventricular (LV) end-diastolic volume, LV end-systolic volume, LV stroke volume, right ventricular (RV) end-diastolic volume, RV end-



**Fig 1. Case selection flowchart for the primary analysis.**

<https://doi.org/10.1371/journal.pone.0194434.g001>

systolic volume, RV stroke volume, and LV mass (Table 2). The interaction terms between the primary exposure variables and sex were not statistically significant and thus there were no differences in the observed relationships between males and females. The linear relationships between CMR-derived parameters and FEV<sub>1</sub> and FVC are shown in the S1 and S2 Figs, respectively.

In a similar multivariable linear model, increasing age was associated with smaller LV end-diastolic volume (−3.96ml, −6.01ml to −1.92ml), LV end-systolic volume (−1.52ml, −2.86ml to −0.17ml), LV stroke volume (−2.47ml, −3.73ml to −1.20ml), RV end-diastolic volume (−5.30ml, −7.49ml to −3.11ml), RV end-systolic volume (−3.03ml, −4.47ml to −1.59ml), and RV stroke volume (−2.30ml, −3.57ml to −1.03ml) (Table 3). Values represent the mean and lower and upper 95% confidence intervals for the change in CMR-derived parameter per

**Table 1. Baseline characteristics of the study population by tertile of FEV<sub>1</sub>.**

	Tertile of FEV <sub>1</sub>			P value
	1 <sup>st</sup> (n = 475)	2 <sup>nd</sup> (n = 468)	3 <sup>rd</sup> (n = 463)	
Age (years)	57.6 (6.6)	53.8 (7.8)	52.3 (7.5)	< 0.001
Sex (male)	41 (9%)	162 (35%)	396 (86%)	< 0.001
Height (cm)	163 (7)	168 (7)	177 (7)	< 0.001
Weight (kg)	68 (13)	73 (15)	82 (13)	< 0.001
Diastolic BP (mmHg)	78 (10)	78 (10)	80 (9)	0.002
Systolic BP (mmHg)	137 (19)	135 (18)	137 (16)	0.976
Resting heart rate (beats per minute)	72 (10)	69 (11)	68 (12)	< 0.001
Townsend deprivation index	-1.99 (2.76)	-2.01 (2.66)	-1.84 (2.75)	0.388
Hypertension	128 (27%)	130 (28%)	121 (26%)	0.852
Diabetes	22 (5%)	15 (3%)	22 (5%)	0.423
Obstructive spirometry <sup>a</sup>	63 (13%)	34 (7%)	19 (4%)	< 0.001
Smoking history (pack years)	4.71 (10)	4.87 (11)	5.23 (11)	0.448
Educational level (degree or professional qualification)	312 (66%)	304 (65%)	314 (68%)	0.632
Ethnicity (white)	456 (97%)	457 (98%)	455 (98%)	0.428
Alcohol consumption (three or more drinks per week)	88 (19%)	87 (19%)	98 (21%)	0.524

Data represent mean (standard deviation) or n (percentage) for continuous and categorical variables, respectively.

The cut-offs between the first and second and second and third tertiles, of FEV<sub>1</sub> were 2.5 litres and 3.09 litres, respectively.

P values by ANOVA or Chi-squared test.

<sup>a</sup>Obstructive spirometry defined as an FEV<sub>1</sub> to FVC ratio < 0.7.

<https://doi.org/10.1371/journal.pone.0194434.t001>

decade increase in age. FEV<sub>1</sub>, FVC, and age did not influence right or left ventricular ejection fraction. Age did not influence left ventricular mass. The relative effect sizes of FEV<sub>1</sub>, FVC, and age on CMR-derived parameters are shown in Fig 2.

In a sensitivity analysis employing a broader definition of acceptable spirometry (at least two ‘acceptable’ blows with no restriction on the range or coefficient of variation of these blows) 2,070 individuals met the criteria for inclusion. There were minimal changes to the

**Table 2. Effects of lung function on CMR-derived parameters.**

CMR Parameter	FEV <sub>1</sub> (standardised)				FVC (standardised)			
	Effect estimate	95% CI		P value	Effect estimate	95% CI		P value
		Lower	Upper			Lower	Upper	
Left ventricular end-diastolic volume (ml)	-5.21	-7.42	-3.00	< 0.001	-5.69	-8.03	-3.36	< 0.001
Left ventricular end-systolic volume (ml)	-2.34	-3.78	-0.89	0.002	-2.56	-4.09	-1.03	0.001
Left ventricular stroke volume (ml)	-2.85	-4.22	-1.49	< 0.001	-3.11	-4.55	-1.67	< 0.001
Left ventricular mass (g)	-2.29	-3.77	-0.82	0.002	-2.46	-4.02	-0.89	0.002
Left ventricular ejection fraction (%)	NS	-0.55	0.60	0.927	NS	-0.56	0.65	0.886
Right ventricular end-diastolic volume (ml)	-5.62	-7.98	-3.26	< 0.001	-5.84	-8.34	-3.34	< 0.001
Right ventricular end-systolic volume (ml)	-2.47	-4.03	-0.92	0.002	-2.46	-4.10	-0.82	0.003
Right ventricular stroke volume (ml)	-3.13	-4.50	-1.76	< 0.001	-3.36	-4.81	-1.91	< 0.001
Right ventricular ejection fraction (%)	NS	-0.68	0.48	0.739	NS	-0.78	0.44	0.588

Effect sizes represent the change of the CMR parameter per standard deviation reduction in FEV<sub>1</sub> or FVC in a multivariable linear regression adjusted for age, sex, ethnicity, height, weight, systolic blood pressure, resting heart rate, Townsend deprivation index, education level, regular alcohol consumption, smoking history, and any diagnosis of hypertension or diabetes. CI; confidence interval. NS; not statistically significant.

<https://doi.org/10.1371/journal.pone.0194434.t002>

**Table 3. Effects of age on CMR-derived parameters.**

CMR Parameter	Age (decades)			P value
	Effect estimate	95% CI		
		Lower	Upper	
Left ventricular end-diastolic volume (ml)	-3.96	-6.01	-1.92	< 0.001
Left ventricular end-systolic volume (ml)	-1.52	-2.86	-0.17	0.027
Left ventricular stroke volume (ml)	-2.47	-3.73	-1.20	< 0.001
Left ventricular mass (g)	NS	-2.58	0.16	0.083
Left ventricular ejection fraction (%)	NS	-0.39	0.67	0.614
Right ventricular end-diastolic volume (ml)	-5.30	-7.49	-3.11	< 0.001
Right ventricular end-systolic volume (ml)	-3.03	-4.47	-1.59	< 0.001
Right ventricular stroke volume (ml)	-2.30	-3.57	-1.03	< 0.001
Right ventricular ejection fraction (%)	NS	-0.13	0.94	0.142

Effect sizes represent the change of the CMR parameter per decade increase in age in a multivariable linear regression adjusted for FEV<sub>1</sub>, FVC, sex, ethnicity, height, weight, systolic blood pressure, resting heart rate, Townsend deprivation index, education level, regular alcohol consumption, smoking history, and any diagnosis of hypertension or diabetes. CI; confidence interval. NS; not statistically significant

<https://doi.org/10.1371/journal.pone.0194434.t003>


effect sizes in the multivariable linear regression, and the 95% confidence intervals were narrower on account of the larger sample size (S2 File). There were no changes to the direction or statistical significance of the results.

## Discussion

The key finding of our study is that in a large cohort of individuals without prior diagnosis of cardiorespiratory disease, lower lung function is associated with smaller left and right ventricular end-systolic, end-diastolic, and stroke volumes; and with lower left ventricular mass. These relationships are independent of other variables known to affect cardiac structure. There was no association with ejection fraction.

The results of our study confirm and expand on previous work. The Multi Ethnic Study of Atherosclerosis (MESA) lung substudy has previously identified relationships between emphysema severity, quantified by thoracic computed tomography, and right and left ventricular volumes and mass[9,10,18], although the consistency of the relationships varied between analyses, and many of the patients had diagnoses of cardiovascular and respiratory disease. In the same cohort, reduced FEV<sub>1</sub> to FVC ratio was associated with LV end-diastolic volume and LV stroke volume[10], and with RV mass[9] although associations with FEV<sub>1</sub> and FVC *per se* were not studied. Using echocardiography, Watz and colleagues[19] showed that LV end-diastolic diameter and RV diameter are associated with FEV<sub>1</sub>. Our study extends these previous findings to a cohort without diagnosed heart or lung disease, and demonstrates consistent relationships between spirometry and multiple measures of left and right ventricular structure and function. The effect sizes seen in this study (2.29ml to 5.84ml per standard deviation change in FEV<sub>1</sub> or FVC) are comparable to those seen in MESA[10] and in echocardiographic studies[19]. Furthermore, they are comparable in size to the effects of systolic and diastolic blood pressure, and diabetes, all widely accepted drivers of ventricular remodelling[20].

Age is a significant risk factor for cardiovascular morbidity and mortality[21,22], and is associated with the development of ventricular fibrosis, remodelling, and diastolic dysfunction [23]. Previous investigations have explored the relationship between age and ventricular structure and function. Analysis of a subset of the UK Biobank CMR study, free from all reported



**Fig 2. Effect sizes for the change in CMR-derived parameter per standard deviation reduction in FEV<sub>1</sub> and FVC, and per one decade increase in age.** Filled shapes represent the change in the CMR-derived parameter per standard deviation reduction in FEV<sub>1</sub> or FVC, or per decade increase in age. Error bars represent the 95% confidence interval for the effect estimate.

<https://doi.org/10.1371/journal.pone.0194434.g002>

comorbid disease[13] showed a statistically significant negative correlation between age and LV and RV end-diastolic, end-systolic, and stroke volumes; and LV mass. Similar relationships were found using the MESA dataset[24,25], and in the current study population.

In the current study, the variation in ventricular volumes and mass seen with lower FEV<sub>1</sub> and FVC is comparable to that seen with ageing. Notably, the changes in CMR-derived parameters per standard deviation of FEV<sub>1</sub> and FVC are approximately the same as those seen with one decade of ageing. This suggests lower lung function is associated with a ‘pre-mature ageing’ effect on the ventricle. This provides potential insight into the mechanisms responsible for adverse cardiovascular outcomes in those with deranged lung function, and



highlights the potential importance of measuring lung function as a marker of cardiovascular 'ageing' and risk.

Our analysis did not identify any relationship between ejection fraction and FEV<sub>1</sub>, FVC, or age, despite the significant influence of these factors on other measures of ventricular function. Similar results were found in a MESA analysis of individuals with emphysema[10]. Our results add to the evidence that ejection fraction alone is an insensitive marker of cardiac function and remodelling, particularly as it relates to respiratory function.

This study has several limitations. The design of UK Biobank renders it liable to selection bias, and it is likely that the population recruited to the study is not completely representative of the population as a whole. The self-reporting of co-morbidities and lifestyle factors such as smoking is liable to ascertainment bias. The relatively low prevalence of smoking observed in our study population may be explained, at least in part, by these two factors.

Many participants were excluded from the analysis as their spirometry did not meet conventional criteria for reproducibility and validity. It is possible that the variability in spirometry arose from its acquisition in the non-specialist UK Biobank assessment centre, rather than in a dedicated pulmonary function laboratory. Furthermore, the study protocol limited participants to producing three blows, rather than repeating the measurement until valid and reproducible results were achieved, as is commonly done in clinical practice. Nonetheless, even after individuals with unacceptable variation had been excluded the full range of FEV<sub>1</sub> and FVC were represented, and thus the ability to examine relationships between these parameters and cardiac structure was preserved. Furthermore, the sensitivity analysis revealed that exclusion of these individuals did not materially affect the results, and suggests that no significant selection bias was introduced by the exclusion of individuals with unacceptable spirometry. The inclusion only of individuals with reproducible, high quality spirometry increases the confidence in the relationships identified by this study.

This study raises a number of questions worthy of further analysis, including the long term cardiovascular outcomes of individuals with subclinical changes in lung function, the changes in cardiovascular phenotype over time in those with deranged spirometry, and evaluation of ventricular fibrosis in participants with impaired lung function through T1 mapping. These will be amenable to investigation as longitudinal follow-up and parametric mapping data become available from UK Biobank.

## Conclusions

In a large cohort of patients without known cardiorespiratory disease, lower FEV<sub>1</sub> and FVC are associated with smaller left and right ventricular volumes, and lower left ventricular mass. The changes in ventricular structure per standard deviation fall in FVC and FEV<sub>1</sub> are similar to those seen with a one decade increase in age, and may shed light on the mechanisms underlying increased cardiovascular risk in those with subclinical changes in lung function, as well as the importance of lung function as a risk factor for cardiovascular disease.

## Supporting information

**S1 File. Definitions of existing cardiorespiratory disease.**

(DOCX)

**S2 File. Sensitivity analysis exploring the impact of a less restrictive definition of valid and reproducible spirometry that included all participants with at least two 'acceptable' blows (as determined by the spirometer) without limitation on the coefficient of variation or**

**difference between the best and second best blow.**  
(DOCX)

**S1 Fig. Univariable associations between CMR-derived parameters and FEV<sub>1</sub>.** Each panel shows the association between one CMR-derived parameter and FEV<sub>1</sub> prior to the standardisation of the lung function. R<sup>2</sup> is the coefficient of explained variance, calculated as the square of the Pearson correlation coefficient between the CMR-derived parameter and FEV<sub>1</sub> on a complete pairs basis.

(TIF)

**S2 Fig. Univariable associations between CMR-derived parameters and FVC.** Each panel shows the association between one CMR-derived parameter and FVC prior to standardisation of the lung function. R<sup>2</sup> is the coefficient of explained variance, calculated as the square of the Pearson correlation coefficient between the CMR-derived parameter and FVC on a complete pairs basis.

(TIF)

## Acknowledgments

This study was conducted using the UK Biobank resource under access application 2964.

## Author Contributions

**Conceptualization:** Ross J. Thomson, Nay Aung, Paul E. Pfeffer, Alexander J. Mackay, Tricia M. McKeever, Charlotte E. Bolton, Stefan K. Piechnik, Stefan Neubauer, Steffen E. Petersen.

**Data curation:** Aaron M. Lee.

**Formal analysis:** Ross J. Thomson.

**Funding acquisition:** Stefan K. Piechnik, Stefan Neubauer, Steffen E. Petersen.

**Investigation:** Ross J. Thomson, Nay Aung, Mihir M. Sanghvi, Jose Miguel Paiva, Filip Zemrak, Kenneth Fung, Elena Lukaschuk, Valentina Carapella, Young Jin Kim.

**Methodology:** Ross J. Thomson, Nay Aung, Tricia M. McKeever, Charlotte E. Bolton, Stefan K. Piechnik, Stefan Neubauer, Steffen E. Petersen.

**Project administration:** Stefan K. Piechnik, Stefan Neubauer, Steffen E. Petersen.

**Resources:** Aaron M. Lee, Stefan K. Piechnik, Steffen E. Petersen.

**Software:** Aaron M. Lee.

**Supervision:** Nay Aung, Steffen E. Petersen.

**Validation:** Nay Aung, Jose Miguel Paiva.

**Visualization:** Ross J. Thomson.

**Writing – original draft:** Ross J. Thomson.

**Writing – review & editing:** Nay Aung, Mihir M. Sanghvi, Jose Miguel Paiva, Aaron M. Lee, Filip Zemrak, Kenneth Fung, Paul E. Pfeffer, Alexander J. Mackay, Tricia M. McKeever, Elena Lukaschuk, Valentina Carapella, Young Jin Kim, Charlotte E. Bolton, Stefan K. Piechnik, Stefan Neubauer, Steffen E. Petersen.

## References

1. European Respiratory Society. The burden of lung disease. In: Gibson J, Loddenkemper R, Sibille Y, Lundback B, editors. European Lung White Book. European Respiratory Society; 2017. pp. 1–14. <http://erswhitebook.org>
2. Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? *Heart*. BMJ Publishing Group Ltd and British Cardiovascular Society; 2012; 98: 1055–1062. <https://doi.org/10.1136/heartjnl-2012-301759> PMID: 22739636
3. Curkendall SM, Lanes S, de Luise C, Stang MR, Jones JK, She D, et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. *Eur J Epidemiol*. Kluwer Academic Publishers; 2006; 21: 803–813. <https://doi.org/10.1007/s10654-006-9066-1> PMID: 17106760
4. Schünemann HJ, Dorn J, Grant BJ, Winkelstein W, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. *Chest*. 2000; 118: 656–664. PMID: 10988186
5. Sin DD, Wu L, Man SFP. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. *Chest*. 2005; 127: 1952–1959. <https://doi.org/10.1378/chest.127.6.1952> PMID: 15947307
6. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. *BMJ*. BMJ Group; 1996; 313: 711–5—discussion 715–6.
7. Martinez CH, Mannino DM, Jaimes FA, Curtis JL, Han MK, Hansel NN, et al. Undiagnosed Obstructive Lung Disease in the United States. Associated Factors and Long-term Mortality. *Ann Am Thorac Soc*. American Thoracic Society; 2015; 12: 1788–1795. <https://doi.org/10.1513/AnnalsATS.201506-388OC> PMID: 26524488
8. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *The European respiratory journal*. European Respiratory Society; 2005. pp. 319–338. <https://doi.org/10.1183/09031936.05.00034805> PMID: 16055882
9. Grau M, Barr RG, Lima JA, Hoffman EA, Bluemke DA, Carr JJ, et al. Percent emphysema and right ventricular structure and function: the Multi-Ethnic Study of Atherosclerosis-Lung and Multi-Ethnic Study of Atherosclerosis-Right Ventricle Studies. *Chest*. 2013; 144: 136–144. <https://doi.org/10.1378/chest.12-1779> PMID: 23450302
10. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. *N Engl J Med*. 2010; 362: 217–227. <https://doi.org/10.1056/NEJMoa0808836> PMID: 20089972
11. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015; 12: e1001779. <https://doi.org/10.1371/journal.pmed.1001779> PMID: 25826379
12. Petersen SE, Matthews PM, Francis JM, Robson MD, Zemrak F, Boubertakh R, et al. UK Biobank's cardiovascular magnetic resonance protocol. *J Cardiovasc Magn Reson*. BioMed Central; 2016; 18: 8. <https://doi.org/10.1186/s12968-016-0227-4> PMID: 26830817
13. Petersen SE, Aung N, Sanghvi MM, Zemrak F, Fung K, Paiva JM, et al. Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort. *J Cardiovasc Magn Reson*. BioMed Central; 2017; 19: 417. <https://doi.org/10.1186/s12968-017-0327-9> PMID: 28178995
14. UK Biobank. UK Biobank—Breath Spirometry [Internet]. 1st ed. 2011. [www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk)
15. Tu Y-K, Clerehugh V, Gilthorpe MS. Ratio variables in regression analysis can give rise to spurious results: illustration from two studies in periodontology. *Journal of Dentistry*. 2004; 32: 143–151. <https://doi.org/10.1016/j.jdent.2003.09.004> PMID: 14749086
16. Kronmal RA. Spurious Correlation and the Fallacy of the Ratio Standard Revisited. *Journal of the Royal Statistical Society Series A (Statistics in Society)*. 1993; 156: 379. <https://doi.org/10.2307/2983064>
17. R Core Team. R [Internet]. Vienna, Austria. [www.r-project.org](http://www.r-project.org)
18. Kawut SM, Poor HD, Parikh MA, Hueper K, Smith BM, Bluemke DA, et al. Cor pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the MESA COPD study. *J Am Coll Cardiol*. 2014; 64: 2000–2009. <https://doi.org/10.1016/j.jacc.2014.07.991> PMID: 25440095
19. Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. *Chest*. 2010; 138: 32–38. <https://doi.org/10.1378/chest.09-2810> PMID: 20190002
20. Heckbert SR, Post W, Pearson GDN, Arnett DK, Gomes AS, Jerosch-Herold M, et al. Traditional Cardiovascular Risk Factors in Relation to Left Ventricular Mass, Volume, and Systolic Function by Cardiac

- Magnetic Resonance Imaging. *J Am Coll Cardiol*. 2006; 48: 2285–2292. <https://doi.org/10.1016/j.jacc.2006.03.072> PMID: [17161261](https://pubmed.ncbi.nlm.nih.gov/17161261/)
21. Dhingra R, Vasan RS. Age as a risk factor. *Med Clin North Am*. 2012; 96: 87–91. <https://doi.org/10.1016/j.mcna.2011.11.003> PMID: [22391253](https://pubmed.ncbi.nlm.nih.gov/22391253/)
  22. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. *Circulation*. 1999; 99: 1165–1172. PMID: [10069784](https://pubmed.ncbi.nlm.nih.gov/10069784/)
  23. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA*. 2003; 289: 194–202. PMID: [12517230](https://pubmed.ncbi.nlm.nih.gov/12517230/)
  24. Cheng S, Fernandes VRS, Bluemke DA, McClelland RL, Kronmal RA, Lima JAC. Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the Multi-Ethnic Study of Atherosclerosis. *Circ Cardiovasc Imaging*. American Heart Association, Inc; 2009; 2: 191–198. <https://doi.org/10.1161/CIRCIMAGING.108.819938> PMID: [19808592](https://pubmed.ncbi.nlm.nih.gov/19808592/)
  25. Zemrak F, Ahlman MA, Captur G, Mohiddin SA, Kawel-Boehm N, Prince MR, et al. The relationship of left ventricular trabeculation to ventricular function and structure over a 9.5-year follow-up: the MESA study. *J Am Coll Cardiol*. 2014; 64: 1971–1980. <https://doi.org/10.1016/j.jacc.2014.08.035> PMID: [25440091](https://pubmed.ncbi.nlm.nih.gov/25440091/)